Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Research
HCL2025 guidelines
The HCLF and LLS joining forces to expanding research in Hairy Cell Leukemia to better characterize its biology, develop new therapies, and optimize o…
News
Study in Nature Medicine Shows Superior Outcomes for Patients in LLS's Paradigm-Shifting Beat AML Clinical Trial
Bringing Precision Medicine to AML patients: LLS’S Beat AML® Master Clinical Trial
OncoPep Strengthens Pipeline with Addition of Multi-Tumor Antigen Adoptive T Cell Therapy
BOSTON – October 15, 2020 – OncoPep, Inc. today announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the developm…
Patient Education Webcasts
Understanding Myeloma
X4 Pharmaceuticals Announces FDA Fast Track Designation Granted to Mavorixafor for the Treatment of WHIM Syndrome
BOSTON, Oct. 08, 2020 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resul…
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
GAITHERSBURG, MD -- October 6, 2020 – NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T …
Affimed Doses First Patient in Phase 1 Clinical Trial of Natural Killer Cells in Combination with AFM13
Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their i…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
